|
Controlling drug costs, optimal infliximab dosage, new treatment guidelines and more in today's rheumatology news update
|
In today's news roundup from Rheumatology Network, we highlight the week's most popular stories beginning with a quick review of ACR's recomme
ndations for controlling drug costs and improving outcomes.
|
|
Read more
|
| |
|
RA Q&A with the Investigator
|
In this Q&A, Dr. Roy Fleischmann, the primary investigator for the phase three clinical trial of upadacitinib (Rinvoq, AbbVie), compares the new rheumatoid arthritis treatment to other treatments.
|
|
Read more
|
| |
